

Outcome: Better access to medical products of diseases type II, III and specific R&D need of developing countries on Type I

Goals: Improved R&D capacities, increased financing and better coordination

Principles:
Supplementary mechanisms to the existing R&D and IP rewards, to correct market failure by delinking R&D investment from prices of medical products

Tools increase financing R&D:
Existing Tools
• Voluntary mechanisms [DNDI, UNITAID, AMC, Prize etc.]
New Tools
• Tax
• Legally binding Convention on financing R&D

Increase access to medical products:
Voluntary mechanisms
• GFATM, GAVI, UNITAID,
• Donation by philanthropic foundations

Others
Normative works
• Global H R&D Observatory, resource tracking systems and coordination
R&D capacities
• Technology transfer

The way forwards
• Understanding the subject matters,
• Engaging stakeholders, MOST, MOH, MOF, etc.
• Form national positions
Processes:
• Formal informal
• Open-ended Intergovernmental Negotiating Body
• Regional consultation and role of regional committee:

Key information required in making decisions
• Effectiveness and political feasibility of different tools
• Sustainability of tools
• Size of finance needed